XPAND protein labeling collaboration unites enGenes with ACIB
Press Release | enGenes Biotech GmbH
APRIL 19, 2018
Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has announced the formation of the XPAND collaboration with ACIB GmbH to develop site-specific incorporation of non-native amino acids into proteins.
The new technology will be based on the enGenes-X-press platform for growth-decoupled protein production in Escherichia coli (E.coli), with expansion of the genetic code.
The Austrian Research Promotion agency (FFG) will fund the XPAND project as a BRIDGE 1 project, to close the “funding gap” between basic and applied research.
Cutting edge technology
“We are very excited about this new project, which underlines that enGenes Biotech is working on the cutting edge of industry relevant innovation,” commented enGenes CEO Dr. Juergen Mairhofer.
“Site-specific labelling is currently very inefficient and alternative approaches are leading to product heterogeneity. Our new approach will be more cost effective with higher labelling efficiencies to promote site specific labeling or conjugation of payload that is so relevant to antibody fragment drug conjugates, for example,” added Dr. Birgit Wiltschi, ACIB’s Junior Group Leader Synthetic Biology, ACIB GmbH.
Cheaper site-specific protein labeling
The business case for the project lies in the expensiveness of non-native (non canonical) amino acids as additives. Using enGenes-X-press technology should allow the partners to save resources and reduce cost by ensuring that the precious non-native amino acids are solely targeted upon the specific protein of interest.
“We aim to offer biopharma companies, CMOs, vaccine manufacturers, industrial biotech companies and start-ups a technology that provides them with a more efficient approach for site-specific labelling of proteins,” said Dr. Mairhofer.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
About ACIB GmbH
The Austrian Centre of Industrial Biotechnology (acib) is an international Research Centre for Industrial Biotechnology with locations in Vienna, Graz, Innsbruck, Tulln, Vienna (A), Hamburg, Heidelberg, Bielefeld (D), Pavia (I) and Barcelona (E), Canterbury (AUS), New Zealand (NZL) and Taiwan. Using the concepts of nature, acib-scientists replace traditional industrial methods with new, more economic and ecological technologies.
Actually, acib is an international network of 150+ international universities and industry partners, including BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Jungbunzlauer or VTU Technology. Owners are the Universities of Innsbruck and Graz, Graz University of Technology, the University of Natural Resources and Life Sciences, Vienna and Joanneum Research.
At acib 250+ scientific employees with up to 30+ years of experience in industrial biotechnology work in more than 170 research projects. The competence center acib is sponsored within COMET (Austrian Competence Centres for Excellent Technologies) by the BMVIT, BMWFW and the provinces of Styria, Tyrol, Lower Austria and Vienna. The COMET program is handled by the FFG.
Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Click on enGenes announces XPAND protein labeling collaboration for more information.
Click on enGenes Biotech GmbH to contact the company directly.